The induction of angiogenesis is a critical point in the development of most human tumors -including melanomas. Some of the earliest studies in the field of tumor angiogenesis showed that transplantation of human melanoma fragments into the hamster cheek pouch stimulated blood vessel growth. Since then, numerous studies have demonstrated that human melanomas also induce angiogenesis. The prognostic importance of the degree of melanoma vascularization, however, has remained controversial. Elevated expression of several angiogenic factors, including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8, has been detected in primary cutaneous melanomas, and the importance of these mediators in promoting melanoma angiogenesis and metastasis has been confirmed in tumor xenotransplant models. Based upon these findings, several clinical trials of angiogenesis inhibitors have been initiated in human melanoma patients and are currently underway. Recent experimental evidence indicates that tumorassociated lymphangiogenesis also plays an important role in mediating tumor spread to regional lymph nodes. These observations have important implications for prognosis and treatment of human melanomas.
Introduction
The induction of angiogenesis -the generation of new capillary blood vessels from pre-existing vessels -is generally considered as essential to ensure the supply of oxygen and nutrients for malignant tumor growth, invasion, and metastasis (Hanahan and Weinberg, 2000) . Whereas blood vessel growth is tightly controlled under physiological conditions, tumor progression is frequently associated with the acquisition of an angiogenic phenotype, associated with a switch in the balance of pro-and antiangiogenic molecules (Hanahan and Folkman, 1996) . Multiple signals trigger the angiogenic switch, including genetic mutations, metabolic and mechanical stress and inflammatory response mechanisms (Carmeliet and Jain, 2000) . Moreover, a complex interplay between environmental and genetic factors determines the balance and activity of pro-and antiangiogenic factors, which may be specific for distinct tumor types and tumor locations, and which may also be altered during tumor progression (Folkman, 2002) . Recent findings have also indicated that lymphangiogenesis might be involved in melanoma metastasis (Dadras, 2003) . But what is the clinical and experimental evidence that angiogenesis is an important aspect of melanoma progression, and will antiangiogenic therapies be useful in treating these patients?
Tumor angiogenesis in melanoma
New blood vessel formation is a prominent feature of human cutaneous melanomas, indicating that these tumors have angiogenic activity (Mihm et al., 1975) . The observation that cutaneous melanoma cells acquire the capacity to actively induce the growth of new blood vessels dates back to the earliest days of tumor angiogenesis research (Warren and Shubik, 1966; Hubler and Wolf, 1976; Stenzinger et al., 1983) . Warren and Shubick (1966) first observed the induction of tumor angiogenesis after transplantation of human melanoma fragments into the hamster cheek pouch; these results were confirmed in later studies (Hubler and Wolf, 1976) . Using Doppler ultrasound studies, Srivastava et al. (1986) detected tumor blood flow in most melanomas that were more than 0.9 mm thick, but rarely in thinner tumors. The clinical and prognostic significance of tumor angiogenesis for melanoma progression and metastasis, however, has remained controversial. In an initial study of 20 melanomas, Srivastava et al. (1988) reported that the vascular area at the base of melanomas with locoregional or systemic metastases was more than twice that of matched recurrence-free tumors. Subsequent studies, using the lectin Ulex europaeus agglutinin I to detect blood vessels, showed a gradual rise in vascularity as melanocytic tumors progressed. Onset of angiogenesis occurred during the radial growth phase of cutaneous melanomas, although considerable heterogeneity was noted between individual cases (Barnhill et al., 1992) . Moreover, the onset of angiogenesis in thin melanomas was associated with inflammatory regression and with development of the vertical growth phase (Barnhill and Levy, 1993) .
A rise in the mean vascular density was correlated with melanoma progression in subsequent histochemical studies of cutaneous melanomas (Erhard et al., 1997; Marcoval et al., 1997) , and a number of retrospective histological studies have reported an inverse correlation between tumor microvessel density and disease-free and overall survival of melanoma patients (Srivastava et al., 1988; Graham et al., 1994; Straume et al., 1999; Vlaykova et al., 1999) . A recently published prospective study of 417 cutaneous melanoma patients reported that tumor vascularity, as determined by analysis of routine histologic stains, was the most important determinant of overall survival, surpassing tumor thickness (KashaniSabet et al., 2002) . Several other investigators, in contrast, failed to detect any correlation between melanoma vascularization and prognosis.
Using morphometric analysis of Ulex europaeus type I lectin-labeled sections obtained from 86 melanomas with no evidence of recurrence after a minimum followup period of 5 years and of 21 cases with locoregional recurrence and/or metastasis, Carnochan et al. (1991) found that tumor recurrence could not be predicted by any of the derived vascular parameters (vascular length, surface, and volume density) -either independently or when combined with other histological and clinical features. Busam et al. (1995) compared 60 cases of metastasizing and nonmetastasizing cutaneous melanomas that were matched for tumor thickness, age, sex, and anatomic site. In this study, there was no significant difference in the number of microvessels or in the pattern of vascular microarchitecture between metastasizing and nonmetastasizing tumors. Recent computerassisted image analysis of matched cases of 20 nonmetastatic and 20 metastatic cutaneous melanomas revealed a comparable level of vascularization in both tumor types, as determined by immunohistochemical quantification of vessels stained for the vascular junction molecule CD31 (PECAM-1) (M Detmar, unpublished results). More surprisingly, a similar immunohistochemical analysis of primary cutaneous melanomas samples taken from 84 patients showed that the only independent variable associated with disease-free survival was tumor thickness (Breslow classification). The only variable associated with overall survival was depth of tumor infiltration (Clark classification), whereas high levels of vascularity were actually correlated with survival (Ilmonen et al., 1999) .
Thus, the potential prognostic value of tumor vascularization in human cutaneous melanomas remains unresolved. Some of these contradictory results might be explained by the nonstandardized assessments of tumor vascularity -these include 'hot spot' analysis and representative field analysis -and by the various detection methods used to visualize tumor-associated blood vessels (routine histologic stains versus vascular immunostains). As an example, Factor VIII-related antigen has been frequently used to detect tumor vessels, but this protein is only expressed by a fraction of immature, CD31-positive intratumoral blood vessels; so quantification techniques based on the presence of this marker might not include all tumor-associated blood vessels. Moreover, recent evidence has shown that the extent of vascularization does not discriminate between benign premalignant and malignant epithelial experimental and human skin tumors (Weninger et al., 1996; Hawighorst et al., 2001 Hawighorst et al., , 2002 .
Importantly, none of the studies published on melanoma blood vessel quantification have included recently discovered molecular markers that can be used to specifically detect blood vessels and lymphatic vessels in tissue sections (Detmar and Hirakawa, 2002; Oliver and Detmar, 2002) (Table 1) . Additional studies should be performed on primary tumor samples taken from matched cohorts of melanoma patients, with long-term follow-up, to determine whether angiogenesis is a useful prognostic factor for this cancer type. These studies should also include the most recently developed, highly specific and sensitive methods for detecting tumorassociated blood vessels.
Expression of angiogenesis modulators by human melanomas
Multiple proangiogenic factors are produced by primary cutaneous melanoma cells. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (Senger et al., 1983) , is an endothelial cell-specific growth factor and the principal regulator of angiogenesis under normal and pathological conditions in most organs (Dvorak et al., 1995; including the skin (Detmar, 1996) . Using immunohistochemical analyses, the transition of horizontal to vertical growth phase in melanoma was found to be associated with increased VEGF protein expression and accumulation in the tumor stroma (Erhard et al., 1997; Marcoval et al., 1997) . Immunoreactivity for VEGF was also found to be related to melanoma thickness, although VEGF was not found to be a useful prognostic indicator for malignant melanoma (Bayer-Garner et al., 1999; Straume and Akslen, 2001 ). Other studies showed that VEGF was only expressed in 32% of primary melanomas, with increased expression levels in metastases (Salven et al., 1997; Vlaykova et al., 1999) . Although 
Angiogenesis and melanoma M Streit and M Detmar these studies demonstrated that VEGF expression is not as prominent in melanomas as in most epithelial cancers (Dvorak et al., 1995) and, therefore, might not represent the major angiogenic activity in these tumors, the expression of functional VEGF receptors on human melanoma cells suggests the intriguing possibility that VEGF might also exert autocrine effects on the tumor cells themselves (Gitay-Goren et al., 1993; Liu et al., 1995; Graeven et al., 1999; Lacal et al., 2000) . Expression of mRNA for basic fibroblast growth factor (bFGF, FGF-2), a potent angiogenesis factor, has been detected in metastatic and primary invasive melanomas, whereas melanocytes in benign nevi did not express this factor (Reed et al., 1994) . Melanomas that were undergoing regression and dysplastic nevi cells were also observed to express bFGF mRNA, however, and bFGF expression levels were also found to be higher in benign melanocytic nevi than in malignant melanoma cells (Ahmed et al., 1997) . It has even been reported that melanomas with bFGF-positive vessels had a better prognosis when compared with melanomas with bFGF-negative vessels (Straume and Akslen, 2002) , suggesting that bFGF upregulation cannot be correlated with malignant transformation in human melanomas. The recent observation, however, that low bFGF serum concentrations at the beginning of highdose interferon (IFN)-a2b therapy were associated with recurrence-free survival (Dreau et al., 2001) , together with the results of experimental tumor xenotransplant studies (see below), warrants further investigation into the importance of bFGF in melanoma progression.
Several other angiogenic factors have been implicated in the pathology of human melanomas. Interleukin (IL)-8, in particular, was found to be absent from normal epidermis and benign melanocytic lesions but was expressed at high levels in the majority of cutaneous melanomas examined (Nurnberg et al., 1999) . Moreover, in a series of 125 melanoma patients, IL-8 serum levels were found to be elevated, compared to healthy controls, and were correlated with an advanced disease stage and poor progression-free and overall survival (Ugurel et al., 2001) . Immunohistochemical analysis revealed increased expression levels of the angiogenic factors placental growth factor (PlGF; Lacal et al., 2000) , platelet-derived growth factor (PDGF)-AA and -BB (Barnhill et al., 1996) , and angiogenin (Hartmann et al., 1999) in human melanoma tissue samples. However, the prognostic value of these factors and their potential importance for melanoma metastasis remain at present unclear.
Downregulation of endogenous angiogenesis inhibitors has been observed in several epithelial cancers, and has been proposed to enhance tumor progression. In contrast to the large number of studies of proangiogenic molecules, however, little is known about the expression of endogenous angiogenesis inhibitors by melanomas. An inverse correlation between mutations in the tumor suppressor p53 and the expression of the angiogenesis inhibitor thrombospondin (TSP)-1 was found in a study of a series of 99 melanoma samples. Researchers detected a significantly higher incidence of p53 mutations in metastatic tumors, suggesting that acquisition of these mutations, coupled with decreased TSP-1 expression, might promote the metastatic phenotype in malignant melanoma (Grant et al., 1998) .
Angiogenesis in experimental melanoma models
Human melanoma cells synthesize a plethora of angiogenic factors in vitro, including VEGF, bFGF, IL-8, PDGF, and PlGF. The specific biological function of several of these factors has been evaluated in both in vitro angiogenesis models and in xenograft models. VEGF expression was found to be absent in normal melanocytes but upregulated in malignant melanoma cells (Gitay-Goren et al., 1993) . In a series of melanoma cell lines, in vitro VEGF expression was correlated with the degree of tumor angiogenesis and the metastatic potential of in vivo tumor xenografts (Potgens et al., 1995) . Overexpression of VEGF in SK-MEL-2 melanoma cells, which normally express only low baseline VEGF levels, promoted tumor growth, angiogenesis, and metastasis in vivo (Claffey et al., 1996) .
VEGF is a homodimeric, heparin-binding glycoprotein occurring in at least four isoforms of 121, 165, 189, and 201 amino acids because of alternative splicing. The different effects of the various VEGF isoforms were recently studied in the nontumorigenic human WM1341 B melanoma cell line, which was derived from early stage melanoma cells that do not express VEGF . Overexpression of VEGF121 and of VEGF165 by these cells resulted in aggressive tumor growth as mouse xenografts, whereas cells that overexpressed VEGF189 remained nontumorigenic and dormant after injection into mice. This difference was likely to be because of the reduced bioavailability of the VEGF189 isoform, which has high heparin affinity and remains cell associated after secretion. The VEGF165-expressing tumors developed a much denser blood vessel network than tumors that overexpressed VEGF121, which is the predominant isoform detected in human melanomas.
These findings have important implications for the pattern of tumor vascularization that occurs during melanoma progression . In addition to the tumor-type specific expression pattern and activity of different VEGF isoforms, recent results provide evidence that the angiogenic response to a distinct melanomaderived VEGF isoform might be site specific. When SK-MEL melanoma cells that overexpressed murine VEGF164 (the equivalent isoform of human VEGF165) were subcutaneously implanted in mice, they induced blood vessel sprouting of new blood vessels (Claffey et al., 1996) . On the other hand, brain metastases derived from the human melanoma cell line Mel57 that overexpressed VEGF165 co-opted pre-existing intra-and peritumoral vessels without inducing angiogenic sprouting of new vessels (Kusters et al., 2002) .
Basic FGF is expressed by most melanoma cells, but not by normal melanocytes, whereas both types of cells express high-affinity receptors for bFGF (Lazar-Molnar et al., 2000) . Although overexpression of bFGF conferred the capacity for anchorage-independent growth to human and murine melanocytes in vitro, bFGF-transfected melanocytes did not form persisting malignant tumors in vivo, indicating that autocrine bFGF stimulation provides a growth advantage but is not sufficient for the induction of a transformed phenotype (Dotto et al., 1989; Nesbit et al., 1999; Graeven et al., 2001) . Interference with the bFGF pathway in melanoma cells by antisense approaches and overexpression of a dominant-negative mutant FGF receptor 1 was shown to inhibit in vitro cell proliferation and in vivo tumorigenesis (Becker et al., 1989 (Becker et al., , 1992 Yayon et al., 1997) , whereas overexpression of bFGF promoted the in vivo tumor growth and tumor angiogenesis of WM164 melanoma cells (Graeven et al., 2001) . In these studies, downregulation of VEGF expression slowed tumor growth, whereas transfection of a bFGF antisense construct completely inhibited tumor formation, indicating an important autocrine function of bFGF in human melanoma development.
IL-8 and PDGF have also been implicated in the promotion of experimental melanoma growth, angiogenesis, and metastasis (Rofstad and Halsor, 2000) . IL-8 is produced by melanocytes and melanoma cells. It stimulates cell migration, proliferation, and metastasis in an autocrine fashion, as shown in IL-8-transfected nonmetastatic SB-2 melanoma cells (Luca et al., 1997) . Moreover, in D-12 human melanoma xenografts, the incidence of spontaneous metastasis was associated with increased IL-8 expression, and treatment with IL-8 neutralizing antibodies significantly decreased angiogenesis and metastasis formation (Rofstad and Halsor, 2002) . In human WM9 melanoma cells that do not express PDGF, induction of tumor-associated blood vessels and formation of a dense connective tissue stroma were observed after cells were transfected with a PDGF expression vector (Forsberg et al., 1993) .
Recently, a highly patterned system of vascular channels that were devoid of endothelial cells but were instead composed of extracellular matrix, lined externally by tumor cells, was observed in some aggressive human uveal and cutaneous melanomas (Maniotis et al., 1999) . This feature, termed 'vasculogenic mimicry', was also observed after injection of melanoma cells into an ischemic microenvironment that was surgically induced in the hind limbs of nude mice (Hendrix et al., 2002) . This formation of tubular networks could also be created in vitro by growing melanoma cells in threedimensional cultures (Seftor et al., 2001) . The implications of these findings for the pathogenesis and progression of human melanomas are at present unclear.
Therapeutic targeting of angiogenesis in melanoma patients
More than two decades ago, Folkman (1975) proposed that inhibition of tumor angiogenesis might represent a new strategy for treating human cancers. Increasing experimental evidence, obtained predominantly in tumor xenotransplant models, suggests that in addition to epithelial cancers, malignant melanoma growth and progression might also be inhibited by blockade of blood vessel growth (Table 2 ). Several reagents have been developed to block VEGF activity, including neutralizing antibodies against VEGF, fusion proteins of the VEGF121 isoform and diphteria toxin, and small molecules or antibodies that prevent VEGF from binding to or signaling through its receptors on the vascular endothelium. These have been demonstrated to have antitumor and antiangiogenic activity in melanoma models (Yuan et al., 1996; Ferrara and Alitalo, 1999; Wild et al., 2000) . Moreover, studies designed to block (Becker et al., 1989; Plum et al., 2000; Yayon et al., 1997) . Other antiangiogenic strategies that have shown antitumoral efficacy in preclinical melanoma models include blockade/targeting of the urokinase-type plasminogen activator (Min et al., 1996) , Tie-2 receptor ligands (Lin et al., 1998) , the a v integrin receptor (Lode et al., 1999) , and matrix metalloproteinases (Naglich et al., 2001 ). Moreover, overexpression or systemic application of the endogenous angiogenesis inhibitors angiostatin (O'Reilly et al., 1994) , endostatin O'Reilly et al., 1997) , TSP-1 (Miao et al., 2001; Reiher et al., 2002) , TSP-2 , and IL-10 (Huang et al., 1996) has been shown to slow tumor growth in melanoma xenograft models. Recent findings suggest that tumor vasculature expresses a specific set of endothelial cell genes which differ from those expressed by normal nonproliferating blood vessels (St Croix et al., 2000) . Although the expression of many of these genes is shared by angiogenic vessels in nonmalignant conditions, the identification of markers that are specific for proliferating microvascular tumor endothelial cells might lead to new therapeutics designed to specifically target tumorassociated blood vessels. However, it is important to remember that the long-term efficacy of antiangiogenic agents might be limited by the complex biology of aggressive malignant melanomas. Recently, subpopulations of melanoma cells were shown to survive even under conditions of hypoxia and metabolic stress, indicating that they might be able to withstand angiogenesis inhibition , and xenografts of WM239A melanoma cells have been shown to have high levels of heterogeneity, with respect to vascular dependency and tolerance for hypoxia (Yu et al., 2001) .
The treatment options for metastatic malignant melanoma are limited and the prognosis for these patients is poor. Currently, surgical removal of the primary tumor and of the draining regional lymph nodes remains the most effective treatment in patients with nodal disease, whereas systemic mono-, poly , or immunochemotherapy regimens have achieved only marginal response rates without significant impact on patient survival (Cascinelli et al., 2000) . Consequently, early detection and prevention of disease progression has remained the most efficient strategy to reduce melanoma mortality, and innovative therapies for advanced human melanoma are urgently needed. Tumor blood vessels represent an alternative therapeutic target for long-term treatment of melanoma, since tumor progression appears to be angiogenesis dependent and because vascular endothelial cells do not have the genetic instability that allows cancer cells to develop drug resistance (Carmeliet and Jain, 2000) .
The safety, feasibility and efficacy of antiangiogenic therapies for patients with advanced malignant melanoma are currently under investigation in clinical phase I-III trials (Table 3) . The humanized monoclonal antibody Vitaxin, which is directed against the a v b 3 integrin (Posey et al., 2001) , and the angiogenesis inhibitor thalidomide, combined with the cytotoxic agent temozolomide (Hwu et al., 2002) , are currently being tested in clinical trials for patients with metastatic melanoma. The combination of temozolomide and thalidomide was shown to be well tolerated and had antitumor activity in some patients with advanced melanoma (Hwu et al., 2002) . A phase I trial of the angiogenesis inhibitor TNP-470, a derivative of fumagillin, resulted in the induction of long-term stable disease in one patient with progressive metastatic melanoma (Bhargava et al., 1999) . Small molecule inhibitors that target VEGF, FGF, or PDGF tyrosine kinase receptors have also shown some promising results in phase I/II studies of several different types of cancer patients (Morin, 2000) . The efficacy of these reagents in human patients with melanoma, however, is unclear. Since malignant melanoma cells release a number of different proangiogenic factors, a combination of these and other antiangiogenic agents, combined with traditional or low-dose chemotherapy or with immunotherapy, might ultimately be needed to inhibit melanoma growth.
Tumor lymphangiogenesis and metastasis
Tumor metastasis to regional lymph nodes, as detected by analysis of sentinel lymph nodes, frequently represents the first step of melanoma dissemination and serves as an important prognostic indicator. In contrast to the extensive studies on melanoma-associated angiogenesis, however, little is known about the mechanisms by which melanoma cells gain entry into the lymphatic system. The recent identification of lymphatic growth factors (VEGF-C and VEGF-D) and their receptor (VEGFR-3), along with the discovery of lymphaticspecific markers (Table 1) , has provided new tools for studying the formation of tumor-associated lymphatic vessels and their contribution to lymphatic tumor spread.
An increasing number of clinicopathological studies have shown a direct correlation between tumor expression of the lymphangiogenesis factors VEGF-C or VEGF-D and metastatic tumor spread in many human cancers (reviewed in Stacker et al., 2002) , providing evidence for the involvement of lymphangiogenesis in tumor progression. Not much data are available, however, regarding the expression of lymphangiogenesis factors by melanomas. A375 melanoma cells, which express VEGF-C, were found to induce lymphatic vessel growth and to invade lymphatic vessels in the avian chorioallantoic membrane, whereas VEGF-C-negative Malme 3 M melanoma cells had no such effects (Papoutsi et al., 2000) . In human melanomas, VEGF-C mRNA expression was detected by primary cutaneous melanomas (Salven et al., 1998) . VEGF-D protein was detected in tumor cells and in vessels that were adjacent to immunopositive tumor cells, but not in normal melanocytes or in vessels that were distant from the tumors ). This indicates a paracrine regulation of tumor lymphangiogenesis in some melanomas.
Recent studies in animal tumor models have provided direct evidence that increased levels of VEGF-C or VEGF-D promote tumor lymphangiogenesis and lymphatic tumor spread to regional lymph nodes, and that these effects can be suppressed by blocking VEGFR-3 signaling (Karpanen et al., 2001; Mandriota et al., 2001; Skobe et al., 2001a, b; Stacker et al., 2001; He et al., 2002) . Whereas VEGF-C overexpression induced tumor lymphangiogenesis and angiogenesis in MeWo melanoma xenotransplants (Skobe et al., 2001a) , the impact of enhanced levels of VEGF-C or VEGF-D on experimental melanoma metastasis has not yet been studied. These studies have been made possible by the discovery of the lymphatic endothelium-specific marker LYVE-1 -a hyaluronan receptor with homology to CD44 . Antibodies against LYVE-1 can be used to identify and quantify tumor-associated lymphatic vessels. The specificity of LYVE-1 for tumor-associated lymphatic endothelium has been confirmed in a number of experimental tumors, in which all LYVE-1-positive tumor-associated lymphatic vessels also expressed the lymphatic-specific transcription factor Prox1 Oliver and Detmar, 2002; Wigle et al., 2002) .
Taken together, these results indicate that tumorassociated lymphangiogenesis, which is induced by VEGF-C, VEGF-D, or other unidentified growth factors, can lead to proliferation and enlargement of peritumoral and intratumoral lymphatic vessels that have been detected in human melanomas . The ability to promote lymphangiogenesis is likely to enhance the metastatic spread of melanomas. Tumor-associated lymphatic endothelial cells are also likely to be involved in the chemotactic recruitment and intralymphatic transport of melanoma cells. Lymphatic endothelium secretes the chemokine CCL21 (secondary lymphoid chemokine), which binds to CC chemokine receptor 7 (CCR7) (Gunn et al., 1998; Saeki et al., 1999) , leading to chemoattraction and migration of mature dendritic cells from the skin to regional lymph nodes. CCR7 is also expressed by some malignant melanoma cell lines (Muller et al., 2001) , and overexpression of CCR7 in B16 malignant melanoma cells led to a dramatic increase in the incidence of regional lymph node metastases after injection into the footpad of mice (Wiley et al., 2001) . These findings indicate that some tumors might take advantage of molecular mechanisms designed for the physiological immune response to further their metastatic spread.
In conclusion, there is now much evidence to indicate that angiogenesis induction is an important part of melanoma progression, although the significance of melanoma vascularization as a prognostic indicator remains unclear. As an increasing number of angiogenesis inhibitors are being tested on other types of tumors, these trials should be expanded to include melanoma patients with progressive disease. Future studies are needed to investigate whether the expression of lymphangiogenesis factors and the extent of tumor-associated lymphangiogenesis might serve as new prognostic tools for the evaluation of primary cutaneous melanoma. 
